Mir-26b inhibits growth and resistance to paclitaxel chemotherapy by silencing the CDC6 gene in gastric cancer
Introduction : Gastric cancer is one of the most common cancers of the digestive system and is associated with high morbidity and mortality. The aim of this study was to investigate whether miR-26b is involved in the proliferation and resistance to paclitaxel chemotherapy in gastric cancer cells....
Main Authors: | Bochao Zhao, Jiale Zhang, Xiuxiu Chen, Huimian Xu, Baojun Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2018-02-01
|
Series: | Archives of Medical Science |
Subjects: | |
Online Access: | https://www.termedia.pl/Mir-26b-inhibits-growth-and-resistance-to-paclitaxel-chemotherapy-by-silencing-the-CDC6-gene-in-gastric-cancer,19,31738,1,1.html |
Similar Items
-
Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer
by: T. A. Titova, et al.
Published: (2018-07-01) -
Meta-Analysis of Paclitaxel-Based Chemotherapy Combined With Traditional Chinese Medicines for Gastric Cancer Treatment
by: Yicong Li, et al.
Published: (2020-02-01) -
Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure
by: Joji Kitayama, et al.
Published: (2014-01-01) -
Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer
by: Hiroshi Matsumoto, et al.
Published: (2018-04-01) -
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
by: Yasuyuki Kawamoto, et al.
Published: (2017-12-01)